Hemophilia and Non-Cancer Clinical Trials
Below is a list of our current Hemophilia and Non-Cancer Clinical Trials
Sidebar
23.0606: A Long-Term Follow-Up Study in Subjects with Severe Hemophilia A Who Received BMN 270, an Adeno-Associated Virus Vector Mediated Gene Transfer of Human Factor VIII in a Prior BioMarin Clinical Trial
Principal Investigator
Vivek Sharma, MD, FACP
Description
The BMN 270 clinical development program consists of multiple interventional studies designed to assess the safety and efficacy of a single infusion of BMN 270 for at least 5 years post-infusion. This long-term follow-up study is needed to help further understand the long-term safety of BMN 270 beyond 5 years and to assess the durability of efficacy.
FInd more information at ClinicalTrials.gov
23.0263: A Phase 2 Study to Evaluate the Efficacy and Safety of MK-1026 inParticipants with Hematologic Malignancies
Principal Investigator
John Chao, DO
Phase
II
Description
The purpose of this study is to evaluate the safety and efficacy of nemtabrutinib (formerly ARQ 531) in participants with hematologic malignancies of chronic lymphocytic leukemia (CLL)/ small lymphocytic lymphoma (SLL), Richter's transformation, marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), follicular lymphoma (FL), and Waldenström's macroglobulinemia (WM).
FInd more information at ClinicalTrials.gov
08.0388 - Protocol for the Cancer Database and Specimen Repository (CDSR) at the Brown Cancer Center (Previous Lung Repository).
Principal Investigator
Rebecca Redman, M.D.
Description
The mission of the Cancer Database and Specimen Repository (CDSR) is to collect clinical information and samples of human specimens from cancer patients and from control patients for research, and to distribute specimens to researchers for the advancement of science.